ALLGF - Alligator Bio on go with mitazalimab clinical trials in the U.S.

The FDA has signed off Alligator Bioscience's (ALLGF) Investigational new Drug for mitazalimab, a CD40 targeting antibody.The company said that the upcoming Phase 1b/2 OPTIMIZE-1 study that will start in Europe in pancreatic cancer, the IND opens up for later expansion in the US.Mitazalimab drug candidate has previously reported positive data from a Phase 1 study performed by Janssen Biotech, showing a manageable safety profile as well as early signs of efficacy.

For further details see:

Alligator Bio on go with mitazalimab clinical trials in the U.S.